R

Redx Pharma PLC
LSE:REDX

Watchlist Manager
Redx Pharma PLC
LSE:REDX
Watchlist
Price: 15 GBX 31.58% Market Closed
Market Cap: 50.2m GBX

Operating Margin
Redx Pharma PLC

-737.3%
Current
-240%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-737.3%
=
Operating Profit
-31m
/
Revenue
4.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Redx Pharma PLC
LSE:REDX
50.2m GBP
-737%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
496.6B USD
27%
CH
Roche Holding AG
SIX:ROG
259.2B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
212B GBP
24%
CH
Novartis AG
SIX:NOVN
208.2B CHF
33%
US
Merck & Co Inc
NYSE:MRK
251.4B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
209B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
No Stocks Found

Redx Pharma PLC
Glance View

Market Cap
50.2m GBX
Industry
Pharmaceuticals

Redx Pharma Plc engages in the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. The company is headquartered in Macclesfield, Cheshire and currently employs 71 full-time employees. The company went IPO on 2015-03-27. The Company’s product pipeline includes RXC004 and ROC007. Its lead product candidate RXC004, which is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. RXC004 is in Phase I study in combination with nivolumab (OPDIVO- Bristol Myers Squibb, an anti-PD-1 antibody). The RXC007 is a selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in a cell signaling pathway. RXC007 is used for the treatment of fibrotic diseases.

REDX Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-737.3%
=
Operating Profit
-31m
/
Revenue
4.2m
What is the Operating Margin of Redx Pharma PLC?

Based on Redx Pharma PLC's most recent financial statements, the company has Operating Margin of -737.3%.

Back to Top